MDXG
$6.41
Mimedx Group
($.06)
(.93%)
MDXG
Earnings Whisper ®
N/A
Consensus:  $0.00
Revenue:  N/A
Tuesday
Nov 3
Before the open
Score
Grade
Tweet Share Watch
Tweet Share Watch
Latest EPS

What do you expect when MDXG reports earnings?
Beat
Meet
Miss

Where is MDXG's stock price going from here?
Up
Flat
Down
Stock chart of MDXG
Analysts
Summary of analysts' recommendations for MDXG
Score
Grade
Pivots
Resistance
-
-
-

-

Support
-
-
-
Tweet
Growth
Description
MiMedx is an integrated developer, processor and marketer of patent protected regenerative biomaterial products and bioimplants processed from human amniotic membrane. Innovations in Regenerative Biomaterials is the framework behind their mission to give physicians products and tissues to help the body heal itself. Their biomaterial platform technologies include AmnioFix and EpiFix, their tissue technologies processed from human amniotic membrane that is derived from donated placentas. Through their donor program, a mother delivering via full-term Caesarean section birth can elect in advance of delivery to donate the placenta in lieu of having it discarded as medical waste. They process the human amniotic membrane utilizing their proprietary PURION Process, to produce a safe and effective implant.
Peers
Edwards LifesciencesIntuitive SurgicalAlign TechnologyWright Medical GroupCryoLifeSTERISLakeland IndustriesInvacare